# MediciNova Shares Phase 2 Trial Results for MN-001 and Outlines Upcoming ALS Milestone

- URL: https://stocks.freetheai.org/news/medicinova-shares-phase-2-trial-results-for-mn-001-and-outlines-upcoming-als-b8bf4f
- Published: 2026-10-12T10:00:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:MNOV](https://stocks.freetheai.org/symbols/NASDAQ-MNOV)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

MediciNova, Inc. (MNOV) issued a shareholder update highlighting findings from a Phase 2 trial of its candidate MN-001 and confirming upcoming milestones for its lead asset, MN-166. The 24-week exploratory study of MN-001 involved 40 patients with nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes. While the trial did not reach statistical significance on its primary endpoints, it showed statistically significant improvements in high-density lipoprotein cholesterol and particle concentration compared to placebo, alongside an early reduction in serum triglycerides.

The company noted that MN-001 was well tolerated with no drug-related serious adverse events, supporting proof of concept and further dataset analysis to determine next steps for the program. The updates come as the biopharmaceutical firm approaches a major catalyst for its lead compound, MN-166, targeting amyotrophic lateral sclerosis (ALS).

MediciNova recently completed the final patient visits in the double-blind portion of the 234-patient COMBAT-ALS trial for MN-166. Topline results for this Phase 2b/3 study remain scheduled for release by the end of 2026. The drug holds Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration.

## Key points

- MediciNova's Phase 2 trial of MN-001 did not hit statistical significance on primary endpoints but showed significant HDL improvements.
- The 24-week study evaluated 40 patients with nonalcoholic fatty liver disease and hypertriglyceridemia linked to type 2 diabetes.
- MN-001 showed a favorable safety profile with no drug-related serious adverse events reported during the study.
- MediciNova completed final patient visits for the COMBAT-ALS Phase 2b/3 trial of lead candidate MN-166, with topline results expected by year-end.

## Questions and answers

### What were the results of MediciNova's Phase 2 trial for MN-001?

The Phase 2 trial of MN-001 did not achieve statistical significance on primary endpoints, but demonstrated statistically significant improvements in HDL cholesterol and particle concentration, as well as an early reduction in serum triglycerides compared to placebo.

### When will MediciNova report trial results for its ALS candidate MN-166?

MediciNova remains on track to report topline results from the COMBAT-ALS Phase 2b/3 trial evaluating MN-166 in 234 patients with ALS by the end of 2026.

### Is MN-001 safe for patients based on the Phase 2 study?

Yes, MN-001 was well tolerated during the 24-week Phase 2 study, with no drug-related serious adverse events reported among participants.